TRAIL has been investigated as a potential therapeutic agent because of its ability to induce apoptosis in cancer cells expressing death receptors that initiate TRAIL-mediated apoptosis and has an advantage over other drugs used for targeting cancer cells because it is a molecule involved in body's natural defense mechanism [13], [35]–[37]. The gene discussed is TNFSF10; the disease is cancer.